1,222 reports of this reaction
5.0% of all BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE reports
#1 most reported adverse reaction
HEADACHE is the #1 most commonly reported adverse reaction for BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, manufactured by Actavis Pharma, Inc.. There are 1,222 FDA adverse event reports linking BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE to HEADACHE. This represents approximately 5.0% of all 24,476 adverse event reports for this drug.
Patients taking BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 1,222 FDA reports for BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 5.0% of all adverse event reports for BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, making it one of the most commonly reported side effect.
If you experience headache while taking BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.